

### REMARKS

Reconsideration of the above-identified application in view of the foregoing amendments and following arguments is respectfully requested. Claim 28 has been added no new matter has been added as a result of this amendment.

The Examiner stated that the drawings did not comply with 37 CFR Section 1.821(d). Applicants thank the Examiner for his careful review. In connection with this objection, Applicants have amended the "Brief Description of the Figures" to include a reference to the appropriate SEQ ID NOS. If the Examiner has any additional questions regarding the figures, he is respectfully requested to contact the undersigned attorney.

Claim 21 is rejected under 35 U.S.C. Section 102(a) as being anticipated by Ema et al., *Biochem. Biophys. Res. Comm.*, 184(1):246-253 (1992) and under Bradfield et al., *Molecular Pharmacology*, 39(11):13-19 (1991). Applicants respectfully traverse this rejection.


Ema et al. disclose the mouse Ah receptor that is 805 amino acids in length. Bradfield et al. disclose the N-terminal amino acid sequence of a mouse Ah receptor. This N-terminal amino acid sequence is 26 amino acids in length. Claim 21 is directed to an amino acid sequence of SEQ ID NO: 37. The amino acid sequence of SEQ ID NO: 37 is 72 amino acids in length. Therefore, because Ema et al. and Bradfield et al. do not disclose each and every element of the claimed invention, this rejection should be withdrawn.

Applicants submit that claims 21 and 28 are now in condition for allowance.

If any additional fees are incurred as the result of the filing of this paper, authorization is given to charge deposit account number 23-0785.

Respectfully submitted,

By:




Lisa V. Mueller (Reg. No. 38,978)  
Attorney for Applicant

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER  
500 MADISON STREET  
SUITE 3800  
CHICAGO, IL 60661  
(312)-876-1800

**CERTIFICATE OF MAILING**

I hereby certify that this Amendment is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on a December 22, 2003.



F:\Transfer folder\Kim Anand\Lisa\Patents\HYD\HYD2571P0011US amendment.doc